BETA Beta Drugs Q2 FY27 results (Jul–Sep 2026) and concall
Beta Drugs Ltd reported strong financial performance in H1 FY27, with revenue growing 29.2% YoY and PAT expanding 45% YoY to ₹34 crores. Performance was supported by robust growth in Nivian Lifesciences (+75%) and normalized export expansion (+169% excluding prior-year one-off opportunity sales). Management highlighted zero-to-negligible impact from recent NPPA trade margin capping guidelines and reiterated full-year overall revenue target of ₹535+ crores with sustainable EBITDA margins of 23-24%.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue up 6.5%, net profit up 145.7% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 48 | 54 | 66 | 54 | 50 +4% | 54 +1% | 56 −16% | 58 +6% |
| EBITDA | 6 | 5 | 8 | 5 | 7 +14% | 10 +86% | 10 +35% | 6 +35% |
| Net profit | 1 | 1 | 4 | 2 | 3 +333% | 5 +283% | 6 +40% | 4 +146% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
